Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD6094 film coated · 1 trial · 1 indication
Absolute bioavailability based on AUC0-inf of oral formulation compared to IV adjusted for dose
Assessment of the total radioactivity by measuring the cumulative amount of AZD6094 (savolitinib) excreted (CumAe)
Assessment of the total radioactivity by measuring the cumulative amount of AZD6094 (savolitinib) excreted and expressed as a percentage of the administered dose (CumFe)
| Arm | Type | Description |
|---|---|---|
| AZD6094 (Savolitinib) D5084C00010 | EXPERIMENTAL | All volunteers will receive either a single dose or two doses of AZD6094 (Savolitinib) D5084C00010 |
| Name | Type | Description |
|---|---|---|
| AZD6094 (Savolitinib) film coated tablets 600 mg | DRUG | AZD6094 (Savolitinib) ilm Coated Tablet 200 mg x 3 |
| [14C]-AZD6094 (Savolitinib) Solution for Infusion, 20 μg/mL (NMT 37.0 kBq/5 mL) | DRUG | 14C AZD6094 (Savolitinib) Solution for Infusion (20 μg/mL (NMT 37.0 kBq/5 mL) |
| [14C] AZD6094 (Savolitinib) Oral Solution, 300 mg (NMT 4.1 MBq) | DRUG | 14CAZD6094 (Savolitinib) Oral Solution (300 mg NMT 4.1MBq) |
Inclusion Criteria: 1. Provision of signed and dated, written informed consent prior to any study specific procedures. 2. Healthy male subjects aged 30 to 65 years at the time of signing informed consent with suitable veins for cannulation or repeated venepuncture. 3. Body mass index (BMI) of 18.0 ...
Top 2 of 4 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/GEH200521 |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
AZD6094 film coated is an investigational small molecule being studied in oncology for cancer. It is in Phase 1 clinical development, and the single completed trial enrolled healthy male volunteers rather than patients. It is not an approved medicine, so it is not currently used for routine cancer treatment outside of clinical research.
AZD6094 film coated is developed by AstraZeneca PLC, which trades under the ticker AZN. AstraZeneca is the sponsor of the clinical program for this small molecule oncology candidate.
AZD6094 film coated is in Phase 1 development. One Phase 1 trial has been completed, and no trials are currently active. Because it remains in early clinical development, it is investigational and has not been approved by the FDA for any indication.
One completed Phase 1 study has evaluated AZD6094 film coated: NCT04675021, titled Absolute Bioavailability and ADME Study of Savolitinib in Healthy Male Subjects. It enrolled 8 healthy male volunteers aged 30 years and older in the United Kingdom. The study was uncontrolled, non-randomized, and not double blinded.
Yes. AZD6094 film coated is also known as AZD6094 (Savolitinib) film coated tablets 600 mg, so savolitinib is the same compound referenced under the AZD6094 code name. The 600 mg film coated tablet is the specific formulation described.